GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer

The aim of this trial is to study the safety, pharmacokinetics and preliminary efficacy of the HER2-targeted antibody-drug conjugate GQ1001 in combination with pyrotinib in patients with HER2-positive metastatic breast cancer patients who had failed previous anti-HER2 treatment.

Trial Details

NCT ID
NCT05575804
Phase
PHASE1 / PHASE2
Sponsor
Fudan University
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • GQ1001+pyrotinib
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Having provided written informed consent, and be able to follow clinical trial protocol.
  • Men or women aged 18-75.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1,life expectancy greater than 3 months.
  • Left ventricular ejection fraction (LVEF) ≥50%.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →